Skip to main content

Table 2 Characteristics of FN patients and comparison patients matched on basis of age (±5 years), tumor stage, chemotherapy regimen, and propensity score

From: Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

  FN Patients (n = 295) Comparison Patients (n = 295) P-value*
Demographics
  Age, mean±SD, y     63.3 ± 12.4 63.0 ±12.1 0.108
  Male, %     49.0 50.7 0.674
  Country of Residence
   Australia    2.7 2.7 0.817
   Austria    5.8 9.2  
   Belgium    11.6 11.9  
   France    24.5 18.4  
   Germany    10.2 12.2  
   Greece    2.7 1.7  
   Italy 5.1 7.8    
   Netherlands    8.8 8.5  
   Nordics    7.1 6.5  
   Portugal    1.4 1.7  
   Spain    12.6 12.6  
   Switzerland    2.7 2.4  
   UK and Ireland    4.8 4.4  
NHL
  Tumor Stage
  I     14.6 14.6 ---
  II     16.7 16.7  
  III     19.4 19.4  
  IV     49.3 49.3  
  IPI/FLIPI Score
   IPI Score
    Low   16.4 20.8 0.368
    Intermediate   50.4 50.6  
    High   19.6 17.3  
    Missing   13.6 11.4  
   FLIPI score
    Low Risk   11.4 15.4 0.920
    Intermediate Risk   36.4 23.1  
    Poor Risk   43.2 51.3  
    Missing   9.1 10.3  
   Bone Marrow Involvement    29.6 24.8 0.252
Clinical
  Risk of FN, %
   <20%    27.0 27.0 0.564
   ≥ 20%    73.0 73.0  
  Medical Conditions, %
   Cardiovascular Disease    23.5 25.2 0.615
   Respiratory Disease    7.8 4.8 0.128
   Gastrointestinal Disease    6.1 5.1 0.564
   Renal Disease    3.1 3.4 0.796
   Hepatic/Biliary Disease    2.7 5.8 0.061
   Haematologic/Lymphatic    5.1 3.1 0.221
   Immunologic    5.4 3.7 0.317
   Other    49.0 46.3 0.505
  ECOG PS, %
   0    47.6 52.4 0.182
   1    31.0 31.6  
   2    10.2 7.5  
   3    5.1 3.7  
   4    1.0 0.7  
   Missing    5.1 4.1  
  Hematology
   ANC (X10^9L), mean±SD    5.4 ± 4.5 5.7 ± 3.4 0.794
   Presence  of  Anemia Symptoms,  %    56.8 56.1 0.856
Treatment
  Chemotherapy Regimen, %
   CHOP-14    3.40 3.40 ---
   CHOP-14-R    27.89 27.89  
   CHOP-21    5.44 5.44  
   CHOP-21-R    63.27 63.27  
  Supportive Care, %
   Index Cycle
    G-CSF Prophylaxis   51.7 56.5 0.162
    Anti-Infective FN Prophylaxis   13.3 11.6 0.529
   Pre-Index Cycle
    G-CSF
     Prophylaxis 37.4 41.8 0.074
     Treatment 9.5 6.5 0.128
    Anti-Infective
     FN Prophylaxis 7.8 5.8 0.303
     FN Treatment 1.7 0.3 0.102
    Transfusion   9.5 6.8 0.144
  Index Cycle Number*
  1     42.9 42.9 ---
  2     13.6 13.6  
  3     11.2 11.2  
  4     12.2 12.2  
  5     9.9 9.9  
  6     8.2 8.2  
  7     1.7 1.7  
  8     0.3 0.3  
  Total Number of Cycles (incl. index cycle thru end of course)
  1     10.6 11.2 0.812
  2     11.9 9.5  
  3     13.3 11.6  
  4     12.3 15.3  
  5     12.6 11.6  
  6     24.2 24.8  
  7     4.1 4.1  
  8     10.9 11.9  
  1. *P-values were not calculated for variables used in the matching process and for which there are no differences between groups (i.e., there was an exact match).